Lupin announced that it has received approval for its Tadalafil
Tablets USP, 20 mg from the United States Food and Drug Administration (FDA) to market a generic version of Eli Lilly and Company's Adcirca Tablets, 20 mg. Lupin's Tadalafil Tablets USP, 20 mg is the generic version of Eli Lilly and Company's Adci rca Tablets, 20 mg. It is indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise ability.
Tadalafil Tablets, 20 mg (RLD: Adcirca) had annual sales of pproximately USD 1174.3 million in the US (IQVIA MAT December 2018).
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
